1. Implementing BCR Signaling Inhibitor Therapy in Relapsed CLL

3. This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Program Goals

5. EMA Indications: BCR Signaling Inhibitors for Patients With CLL

6. Ibrutinib Efficacy in the Relapsed Setting

7. Ibrutinib in the Relapsed Setting: Long-Term Outcomes

8. Idelalisib/Rituximab Efficacy in Relapsed CLL

9. Ibrutinib in del(17p) and TP53 Mutated CLL

10. Idelalisib/Rituximab in del(17p) and TP53 Mutated CLL

11. Complex Karyotype in Patients Treated With Ibrutinib

12. Complex Karyotype in Patients Treated With Idelalisib/Rituximab

13. Molecular Testing With FISH and Karyotyping

14. Safety Profile of Ibrutinib

15. Safety Profile of Idelalisib/Rituximab

16. Safety of BCR Signaling Inhibitors: Mitigating Risk for Infection

17. Safety of Ibrutinib: Bleeding-Related Events

18. Safety of Ibrutinib: Atrial Fibrillation

19. Safety of Idelalisib/Rituximab: Colitis and Pneumonitis

20. Safety of Idelalisib/Rituximab: Frontline vs Relapsed Setting

21. Efficacy of Ibrutinib Plus Bendamustine and Rituximab

22. Idelalisib Plus Ofatumumab in Relapsed CLL

23. Selecting a BCR Signaling Inhibitor: Clinical Considerations

24. Sequencing BCR Signaling Inhibitors: Mechanisms of Resistance

25. Sequencing Therapy: Bcl2 Inhibitor Venetoclax

26. Treatment Options After a BCR Signaling Inhibitor

27. Chemoimmunotherapy After a BCR Signaling Inhibitor

28. Looking Ahead: Combination Therapy in CLL

29. Conclusions